(2S)-4-(二(丙-2-基)氨基)-2-苯基-2-吡啶-2-基丁酰胺 | 74464-84-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: (2S)-4-(二(丙-2-基)氨基)-2-苯基-2-吡啶-2-基丁酰胺
• 中文别名: 2-[4-[2-[(4-甲氧苯基)氨基]-1,3-噻唑-4-基]苯氧基]乙酸
• 英文名称: (+)-Disopyramide
• 英文别名: (2S)-(+)-disopyramide；(S)-(-)-disopyramide；S-(+)-disopyramide；S(+)-disopyramide；(S)-disopyramide；S-disopyramide；2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, (S)-；(2S)-4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
• CAS: 74464-84-9
• 化学式: C₂₁H₂₉N₃O
• 分子量: 339.481
• InChiKey: UVTNFZQICZKOEM-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  3

ADMET

代谢

异丙酰胺已知的人类代谢物包括N-去异丙基异丙酰胺。

Disopiramide has known human metabolites that include N-Desisopropyldisopyramide.

来源:NORMAN Suspect List Exchange

反应信息

• 作为反应物：
  描述：

  (2S)-4-(二(丙-2-基)氨基)-2-苯基-2-吡啶-2-基丁酰胺 在 盐酸 、 间氯过氧苯甲酸 、 锌 作用下， 以 乙醇 、 二氯甲烷 、 苯 为溶剂， 反应 1.25h， 生成 (+)-Mono-N-Desisopropyldisopyramide
  参考文献：
  名称：

  Synthesis and anticholinergic properties of the enantiomers of 4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide, the mono-N-dealkylated metabolite of disopyramide

  摘要：

  The 2R and 2S enantiomers of 4-isopropyl-2-(2-pyridyl)-2-phenylbutyramide [(2R)-2 and (2S)-2] were prepared from the respective 2R and 2S enantiomers of disopyramide [(2R)-1 and (2S)-1] by oxidation with peracid, Cope elimination, and subsequent zinc/HCl reduction of the resulting hydroxylamines (2R)-3 and (2S)-3. The enantiomers were tested as antagonists to the contraction of guinea pig ileum longitudinal muscle produced in response to electrically stimulated release of acetylcholine. The enantiomers showed IC50 values of 5.0 X 10(-6) and 14 X 10(-6) M for (2S)-2 and (2R)-2 respectively, about a 3-fold difference between enantiomers. Data are presented showing direct antagonism of acetylcholine in the guinea pig ileum assay. In a comparison of the anticholinergic effects of 2 and 1, the metabolite (2) was slightly less potent than disopyramide (1).

  DOI：

  10.1021/jm00137a024
• 作为产物：
  描述：

  达舒平 生成 (2S)-4-(二(丙-2-基)氨基)-2-苯基-2-吡啶-2-基丁酰胺
  参考文献：
  名称：

  二吡amide酰胺，4-（二异丙基氨基）-2-（2-吡啶基）-2-苯基丁酰胺的对映异构体的拆分，绝对构型和抗心律不齐特性。

  摘要：

  通过从甲醇-丙酮中分步结晶其非对映体酒石酸氢盐来拆分二吡op酰胺。由（+）-樟脑10磺酰氯制备的非对映体磺酰胺和通过LiAlH4还原拆分的碱获得的伯胺可通过高效液相色谱分离，并用于证明在实验误差范围内二吡甲酰胺的拆分完全。绝对构型通过X射线晶体学确定。（+）-[（（2R）-（-）-4-（二异丙基氨基）-2-（2-吡啶基）-2-苯基丁酰胺（+）-（2R，3R）-酒石酸氢盐]在空间群P212121中结晶： 14.789（4），b = 18.151（4），c = 9.878（2）A；Z = 4：Dx = 1.225，Dm（浮选C6H6 / CCl4）= 1.226 g cm-3。该结构通过直接方法解决。测试了对映体酒石酸氢盐的抗心律不齐特性。对映体酒石酸氢盐在延长兔脑室的有效不应期（ERP）方面同样有效。在3 x 10（-6）M时，[-（-）-酒石酸[来自（2S）-（+）-二吡酰胺]使ERP增加21

  DOI：

  10.1021/jm00183a015

文献信息

• [EN] TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS<br/>[FR] ADMINISTRATION CIBLÉE D'UN MÉDICAMENT FAISANT APPEL À DES COUPLEURS FONDÉS SUR L'AFFINITÉ
  申请人：INVICTUS ONCOLOGY PVT LTD

  公开号：WO2015148126A1

  公开（公告）日：2015-10-01

  The current invention discloses targeted drug delivery conjugates comprising a targeting moiety linked to a drug via a molecule having an affinity for the targeting moiety. Typically, the conjugate comprises a targeting ligand and a molecule of interest, e.g., a therapeutic agent. The targeting ligand and the molecule of interest are linked to each other via an affinity ligand. The affinity ligand is further covalently or non-covalently linked to a drug or therapeutic agent. The drug can be modified to make it more soluble and so that it cleaves from the linking molecule at the target site.

  当前的发明揭示了包括通过具有与靶向基团亲和力的分子连接到药物的靶向药物传递共轭物。通常，该共轭物包括一个靶向配体和一个感兴趣的分子，例如，一个治疗剂。靶向配体和感兴趣的分子通过一个亲和配体相互连接。该亲和配体进一步以共价或非共价方式连接到药物或治疗剂。药物可以被修改以使其更溶解，并使其在靶点处从连接分子中解离。
• ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF
  申请人：Meng Charles Q.

  公开号：US20140142114A1

  公开（公告）日：2014-05-22

  The present invention relates to novel anthelmintic compounds of formula (I) below: wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 and X 8 are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.

  本发明涉及以下式（I）的新型驱虫化合物： 其中 Y和Z分别是双环碳环或双环杂环基团，或者Y或Z中的一个是双环碳环或双环杂环基团，另一个是烷基，烯基，炔基，环烷基，苯基，杂环基或杂芳基，以及变量X 1 ，X 2 ，X 3 ，X 4 ，X 5 ，X 6 ，X 7 和X 8 如本文所定义。本发明还提供了包含本发明的驱虫化合物的兽药组合物，以及它们用于治疗和预防动物寄生虫感染的用途。
• [EN] ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS<br/>[FR] COMPOSÉS DEPSIPEPTIDIQUES ANTHELMINTHIQUES
  申请人：MERIAL INC

  公开号：WO2018093920A1

  公开（公告）日：2018-05-24

  The present invention provides cyclic depsipeptide compounds of formula (I) wherein the stereochemical configuration of at least one carbon atom bearing the groups Cy1, Cy2, R1, R2, R3, R4, Ra and Rb is inverted compared with the naturally occurring cyclic depsipeptide PF1022A. The invention also provides compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.

  本发明提供了公式（I）的环状脱氨肽化合物，其中至少一个碳原子的立体化学构型与自然存在的环状脱氨肽PF1022A的基团Cy1、Cy2、R1、R2、R3、R4、Ra和Rb相比发生了倒置。该发明还提供了包含这些化合物的组合物，对危害动物的寄生虫具有有效性。这些化合物和组合物可用于对抗哺乳动物和鸟类体内或体表的寄生虫。该发明还提供了一种改进的方法，用于根除、控制和预防鸟类和哺乳动物的寄生虫感染。
• [EN] ANTI PARASITIC DIHYDROAZOLE COMPOUNDS AND COMPOSITIONS COMPRISING SAME<br/>[FR] DIHYDROAZOLES ANTIPARASITAIRES ET COMPOSITIONS LES INCLUANT
  申请人：MERIAL LTD

  公开号：WO2011075591A1

  公开（公告）日：2011-06-23

  The present invention relates to novel dihydroazole of formula (I) and salts thereof: Wherein R1, A1, A2, G, X and Y are as defined in the description, compositions thereof, processes for their preparation and their uses to prevent or treat parasitic infections or infestations in animals and as pesticides.

  本发明涉及式(I)的新型二氢咪唑及其盐：其中R1、A1、A2、G、X和Y如描述中所定义，以及它们的组合物、制备方法以及它们用于预防或治疗动物寄生虫感染或寄生虫侵袭以及作为杀虫剂的用途。
• [EN] P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS P2X3 ET/OU P2X2/3 ET MÉTHODES ASSOCIÉES
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2018064135A1

  公开（公告）日：2018-04-05

  The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R7 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.

  本公开提供了新颖的化合物和制备和使用这些化合物的方法。在一种实施例中，这些化合物具有如下式（I）的结构，其中R1-R7在此处定义。在另一种实施例中，这些化合物在调节P2X3或P2X2/3受体中的一种或两种的方法中是有用的。在另一种实施例中，通过向患者施用一种或多种化合物来治疗患者的疼痛是有用的。在另一种实施例中，通过向患者施用一种或多种化合物来治疗患者的呼吸功能障碍是有用的。